Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma
Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.
Read More
Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.
Read More
Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.
Read More
MRD Negativity as a Trial Outcome and Its Use in Clinical Practice
Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.
Read More
Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma
Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.
Read More
Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates
Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.
Read More
Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje
June 2nd 2024OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference
Read More
BCMA-Targeted CAR-T Therapies in Development and Future Perspective
January 30th 2024Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.
Read More
CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MM
January 23rd 2024Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).
Read More
Evolving Treatment Landscape of Relapsed/Refractory Multiple Myeloma
January 16th 2024Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.
Read More
Unmet Needs and Future Perspectives in Multiple Myeloma Care
The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
Read More
Does Belantamab Have a Place in Multiple Myeloma Treatment?
The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
Read More
Preventing Infection in Patients with Multiple Myeloma During Treatment
Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
Read More
Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
Read More
Targets in Multiple Myeloma: FcRH5
Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
Read More
Targets in Multiple Myeloma: GPRC5D
Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.
Read More
Data Updates on Immunotherapy Combinations in Multiple Myeloma
Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
Read More
Retreatment with a BCMA-Targeting Bispecific for R/R MM
Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
Read More
BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.
Read More
CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.
Read More
Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.
Read More
Quadruplet Combination Therapies in Relapsed Multiple Myeloma
Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.
Read More
Strategies for Treatment of Multiple Myeloma at Late Relapse
The panel debates the options for treatment of late relapsed multiple myeloma.
Read More
Data Updates in the Treatment of Relapsed Multiple Myeloma
Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.
Read More
Relapse in Multiple Myeloma: Biochemical and Chemical
Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
Read More
Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.
Read More